Rezolute remains in a pre-revenue, clinical-stage phase with a meaningful quarterly net loss and no recognized revenue in QQ3 2025. The company posted a net loss of approximately $18.9 million for the quarter and basic earnings per share of -$0.27, driven by ongoing R&D and general and administrative expenses totaling about $20.0 million. Despite the negative near-term earnings trajectory, Rezolute shows a favorable liquidity position with roughly $86.9 million in cash and short-term investments and a robust current ratio (~8.4x), providing a substantial runway to fund its clinical programs. The maturing pipeline (notably RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema) represents longer-term upside, contingent on readouts and potential partnership or licensing deals. Management commentary is not included in the data set, limiting qualitative flavor; however, the balance sheet strength and absence of debt support the ability to fund pipeline activities while awaiting pivotal trial readouts. Key questions for investors center on timing of trial data, potential partnerships, and the company’s ability to secure additional capital if required to sustain operations until products potentially monetize.
Key Performance Indicators
Net Income
Decreasing
-18.91M
QoQ: -20.24% | YoY: -10.93%
EPS
Increasing
-0.27
QoQ: -22.73% | YoY: 20.59%
Revenue Trend
Margin Analysis
Financial Highlights
Overview of QQ3 2025 financials and notable trends (USD in millions, unless stated):
- Revenue: None reported for QQ3 2025; company remains pre-revenue as a clinical-stage biotech. Historical quarterly revenue in the four-quarter window shows a one-off 58 thousand in 2024-Q4, underscoring the absence of product revenue.
- Net income: -$18.914 million for QQ3 2025, a YoY decline of 10.93% and QoQ decline of 20.24% per reported metrics, reflecting ongoing R&D and SG&A burn.
- EPS: -$0.27 per share for QQ3 2025; YoY improvement of 20.59% notwithstanding the net loss, with QoQ deterioration of -22.73%.
- Operating expenses: Total operating expenses $20.023 million (R&D $15.283 million; G&A $4.740 million).
- Cash flow: Net cash used in operating activities of $17.4 million; free cash flow negative by $17.4 million for the quarter; cash and equivalents plus short-term investments totaled $86.892 million at period end.
- Balance sheet health: Total assets $94.739 million; total liabilities $12.17 million; stockholders’ equity ~$82.569 million; cash position of $14.596 million with $72.296 million in short-term investments supporting liquidity. Net debt is negative around $12.821 million, reflecting strong net cash position.
- Liquidity metrics: Current ratio 8.43, quick ratio 8.43, cash ratio 1.39, indicating substantial liquidity headroom relative to near-term liabilities.
- Cash runway: With no evident near-term revenue, the company relies on cash reserves to fund ongoing trials and corporate expenses. The quarterly burn rate implies that liquidity will depend on the continued access to capital or future clinical data readouts that could unlock partnerships or licensing opportunities.
Income Statement
Metric
Value
YoY Change
QoQ Change
Net Income
-18.91M
-10.93%
-20.24%
EPS
-0.27
20.59%
-22.73%
Key Financial Ratios
Return on Assets
Weak
-0.20%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.23%
Return on equity suggests inefficient capital allocation
Current Ratio
Strong
8.43
Current ratio indicates excellent liquidity and financial flexibility
Debt to Equity
Conservative
0.02
Debt-to-equity shows conservative leverage and low financial risk
P/E Ratio
Negative
-2.68x
Negative earnings make P/E ratio not meaningful
Price to Book
Fair Value
2.46x
Price-to-book ratio reasonable for profitable companies
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.